NuVasive

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuVasive is a medical device company that creates minimally invasive surgical products and procedurally integrated spine solutions. Its minimally invasive, procedurally integrated surgical solutions are intended to produce repeatable and clinically proven results.

NuVasive (NUVA) delivered earnings and revenue surprises of 100.00% and 14.09%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Q3 Earnings and Revenues Beat Estimates

SAN DIEGO, Oct. 29, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2020....

NuVasive Announces Third Quarter 2020 Financial Results

SAN DIEGO, Oct. 19, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the Company will release its third quarter 2020 earnings...

NuVasive Announces Conference Call and Webcast of Third Quarter 2020 Results

SAN DIEGO, Oct. 14, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced a new organizational and leadership structure for its...

NuVasive Announces New Organizational Structure to Align Global Commercial Operations and Product & Services Organization with Long-Term Strategy

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

Surmodics

NUVA vs. SRDX: Which Stock Is the Better Value Option?

NUVA or SRDX: Which Is the Better Value Stock Right Now?

NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.

NuVasive's (NUVA) MaXcess Retractor Study Results Positive

NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.

NuVasive Banks on Product Launches Amid Procedural Volume Loss

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- NuVasive, Inc.

NuVasive Expands Precice Portfolio with First-of-its-Kind Plate for Pediatric Limb Lengthening and Reconstruction Procedures

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

Why Is NuVasive (NUVA) Up 1.9% Since Last Earnings Report?

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- NuVasive, Inc.

NuVasive to Participate in Investor Events in September 2020

NuVasive's Valuation Prices In An Excessively Bearish Outlook

NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.

NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss

NuVasive, Inc. (NUVA) CEO Chris Barry on Q2 2020 Results - Earnings Call Transcript

NuVasive (NUVA) delivered earnings and revenue surprises of 18.37% and -0.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Reports Q2 Loss, Misses Revenue Estimates

NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will NuVasive (NUVA) Beat Estimates Again in Its Next Earnings Report?

Abbott Labs

Baxter

Boston Scientific

Edwards Lifesciences

Globus Medical

Johnson & Johnson

Medtronic

Stryker

Health care is supposed to be a very defensive sector in investing. After all, diseases and conditions such as cancer, diabetes, heart disease, kidney failure, dementia, joint damage and spinal issues are just a small percentage of the ailments that have to be routinely treated.

Beyond COVID-19, Credit Suisse Shows Its Top Health Care Recovery Stock Picks

NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NuVasive (NUVA) Expected to Beat Earnings Estimates: Should You Buy?

Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.

NuVasive Launches Reline 3D for Pediatric Patients Globally

A Relative Strength Rating upgrade for Nuvasive shows improving technical performance. Will it continue?

Nuvasive Shows Improved Relative Price Performance; Still Shy Of Benchmark

NuVasive (NUVA) Up 6.6% Since Last Earnings Report: Can It Continue?

SAN DIEGO, June 4, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today that it closed the issuance of an additional $50.0 million in aggregate principal amount of the 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes"), pursuant to the exercise in full of the...

NuVasive, Inc. Announces Full Exercise Of Option By Initial Purchasers To Purchase Additional 1.00% Convertible Senior Notes Due 2023

SAN DIEGO, May 28, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today the pricing of its offering (the "Offering") of $400.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2023 (the "Convertible Notes") in a private placement to qualified...

NuVasive, Inc. Announces Pricing Of Offering Of $400 Million Of 1.00% Convertible Senior Notes Due 2023

SAN DIEGO, May 26, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA) announced today that it intends to offer (the "Offering"), subject to market and other considerations, $400.0 million aggregate principal amount of Convertible Senior Notes due 2023 (the "Convertible Notes") in a...

NuVasive, Inc. Announces Proposed Offering Of $400 Million Of Convertible Senior Notes Due 2023

NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.

News for NuVasive Stock (NUVA)